Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 801–900 of 1,139
Kuryłowicz, A., & Czupryniak, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71226 · Cited by 3
Chen, D., Ma, B., Sun, H., Zhang, J., Gong, L., Wang, W., Liu, Z., Zha, H., Du, S., Chen, M., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2026-003026 · Cited by 1
GLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?
Pichlerová, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.070
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
“When compared with selective GLP-1RAs and the dual agonist tirzepatide, retatrutide demonstrated superior hepatic fat reduction [31, 121].”
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“It has been shown to reach, at a maximum dose, a mean weight loss of −24.2% at 48 weeks [56].”
InfluentialSelective amylin receptor agonism: promise beyond incretins
van Beek, A. P. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02214-7
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_13
Vásquez-Tirado, G. A., Villarreal-Jara, M., Meregildo-Rodríguez, E. D., & Quispe-Castañeda, C. V. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100697
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
A Pragmatic Outpatient Framework for Appetite‐Related Phenotyping in Obesity
Velazquez-Navarro, J. A., Rodríguez‐Moriel, R., Márquez-Herrera, R. M., & Ramos‐Márquez, L. A. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70184
“In patients without a dominant appetite‐related phenotype, where reduced energy expenditure may play a larger role, emerging therapies targeting energy balance, such as the triple agonist retatrutide, may be relevant [32].”
The promise of a new orally active body weight reducer
Volpe, M., & Pedicino, D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad470
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
Wilbrink, J. (2025) · Research Publications (Maastricht University) · doi:10.26481/dis.20250620jw
Physiology and therapeutic insights of incretins in 2026: An update
Hirlemann, M., Phan, A., Carette, C., Beyec, J. L., Ledoux, S., & Gall, M. L. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.08.106
Diabetes Update 2024 – wertvolle neue Erkenntnisse
Scherbaum, W. A. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01205-w
“Die häufigsten Ne-benwirkungen in den Retatrutidgruppen waren gastroenteraler Natur und meist mild bis moderat [2].”
Metabolic Determinants of Weight-Loss Quality During and After Incretin-Based Therapies in Obesity
Luna, M., Rodrigues, B., & Ramalho, A. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100711
Gupta, M., & Shukla, J. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2041_2025 · Cited by 2
Glucagon-like-peptide-1 receptor agonists in diabetes mellitus
Abu, M. S. P., Pradeep, G. K., Baby, B., Premjith, S., Venugopal, A., & Joy, S. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00006-3
Lari, S. A., Zumot, M. S., & Alrashid, M. A. (2026) · Cureus · doi:10.7759/cureus.112694
“This tri-agonist approach appears to delay or bypass the classic biological adaptations that contribute to single-receptor weight-loss plateaus, potentially establishing a new therapeutic ceiling for patients who have exhausted dual-agonist therapies [8,22].”
InfluentialDisease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“…changes, together with a relative reduction in liver fat of 81.4% and 82.4% at the 8 mg and 12 mg doses, respectively, in a phase 2a substudy, in which 86% of participants receiving 12 mg reached a normal liver fat content of less than 5%, suggest a plausible disease-modifying profile [19, 53].”
InfluentialSasankan, D., & Mohan, R. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70283
OBESIDADE E AUTISMO: REVISÃO SISTEMÁTICA E POSSIBILIDADES TERAPÊUTICAS EMERGENTES
Vasconcelos, R. D. (2025) · Revista Contemporânea · doi:10.56083/rcv5n4-057
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Yovera-Aldana, M., Manrique-Hurtado, H., & Umpierrez, G. E. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag260
“However, individuals with PWS have been systematically excluded from these landmark trials, and the role of such intensive incretin-based therapy in this population remains unknown [10].”
Maksimov, M. L., Sidorova, A. D., Kizlik, S. V., & Kizlik, V. A. (2026) · doi:10.33920/med-13-2603-01
Sex differences in central endozepine expression and regulation of appetite
Geisler, C. E., Applebey, S. V., Chichura, K. S., Pelletier, C., Belser, D. L., Hu, J., Harris, E. P., Levine, C. M., Parent, M. B., Bangasser, D. A., et al. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115003
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
“…obesity randomized to retatrutide achieved a mean weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks. while all therapies have variable individual treat-ment responses [9], all participants assigned to retatrutide 8 mg or more weekly responded with at least a 5% weight loss at 48 weeks [44].”
InfluentialPekár, M., Holéczy, P., & Šoltés, M. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004369
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Dueñas, L. G. D., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Flores, H. M. V., Mendoza-Godoy, J. J., Zavaleta‐Gutiérrez, F. E., & Paz‐Ibarra, J. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.118730
Pediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Hsia, S. H., Bays, H. E., Billings, L. K., Weideman, A. M., Mather, K. J., Coşkun, T., Haupt, A., Thomas, M. K., Tham, L. S., Calderón, B., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00160-9 · Cited by 1
Self-citationUlusu, N. N. (2026) · Antioxidants · doi:10.3390/antiox15091143 · Cited by 1
“Reta-trutide transforms WAT into a metabolically important organ, increasing lipid oxidation, decreasing inflammation, and restoring endocrine function [274].”
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“In addition to tirzepatide, next-generation multi-receptor agonists are rapidly moving forward, such as triple receptor agonists like retatrutide, which have shown up to 24.2% weight loss at 48 weeks in phase 2 trials, and other dual-and triple-agonist programs in clinical development [41].”
InfluentialA Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies
Durma, A. C., & Czupryniak, L. (2026) · Nutrients · doi:10.3390/nu18162602 · Cited by 1
“Several novel agents are currently in late-stage clinical development, notably the triple GLP-1/GIP/glucagon receptor agonist retatru-tide [6] and orforglipron—the first oral, small-molecule (non-peptide) GLP-1 receptor agonist to demonstrate meaningful weight loss in phase 3 trials.”
InfluentialEffects of Obesity on Human Health and the Emerging Role of GLP-1 Based Therapies
Bansal, G. (2025) · International journal of high school research · doi:10.36838/v7i3.10
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
Cruz, P., Puebla-Huerta, A., Troncoso, M. F., Silva-Pavez, E., Hidalgo, Y., & Ahumada-Castro, U. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1826699
Dong, Z., Cheng, L., Shi, Q., Luo, Y., Ning, K., Ye, L., Tu, Y., & Shi, Z. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153824
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
He, Q., Shan, H., Hu, W., Xu, H. E., & Zhao, L. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01923-5
Song, E. Y., Melton, M. S., Hammert, W. C., Li, N. Y., & Saltzman, E. B. (2026) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2026.05.008
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Grycan, M., Grycan, G., & Pstrągowski, M. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0015
Tan, H., Chen, X., Tan, X.-Y., Lv, W., Hu, T., Zhu, T., Zhao, Y., Chen, X., & Qian, B. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5360472
Obesity: A Disease of Overnutrition
Champagne, C. M., & Bray, G. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-25402-3_2
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs
Szołkiewicz-Płatkowska, A., & Orczykowski, M. (2024) · In a good rythm · doi:10.5604/01.3001.0054.6436 · Cited by 1
Einladung zur Mitgliederversammlung
(2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2219-1449
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“As treatment duration extends and combination therapy scenarios increase, their long-term adherence and potential effects on cardiometabolic parameters continue to require observation [15,77].”
Fettstoffwechselstörungen bei endokrinen Erkrankungen: Einfluss auf das kardiovaskuläre Risiko
König, A., Bintaro, S., & Leitolf, H. (2024) · CardioVasc · doi:10.1007/s15027-024-3692-y
“24 % [11].”
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
Abud, G. F., de Freitas, E. C., & Stanford, K. I. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00756-x
“Phase 2 clinical data reveal substantial reductions in body weight, exceeding 24% at a 12 mg dose over 48 weeks [113], consistent with potential synergistic metabolic effects of combined GLP-1R, GIPR, and GCGR agonism [114].”
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“20) Finally, the “next-generation” triple agonist Retatrutide (GLP-1/GIP/Glucagon) has demonstrated unprecedented efficacy in phase 2 trials, with weight loss exceeding 24%, challenging the “gold standard” of bariatric surgery.”
Obstructive sleep apnea pharmacology
Sunwoo, B. Y., Schmickl, C. N., & Malhotra, A. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2695024
“81 Of note, there are currently no direct comparisons of tirzepatide to CPAP, such that first line therapy for OSA remains CPAP therapy.”
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
“The triple agonist retatrutide will also be evaluated in subjects with T1DM and obesity or overweight [77].”
Do Heart Failure With Preserved Ejection Fraction Treatments Work by Targeting Adipose Biology?
Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.046 · Cited by 1
James-Okoro, P.-P., Field, J., Davies, G., Pearce, A., Al‐Sabah, S., Lim, K. N., Ladds, G., Hornigold, D. C., Gribble, F. M., & Reimann, F. (2026) · Peptides · doi:10.1016/j.peptides.2026.171507 · Cited by 1
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rhouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E. D. F., et al. (2025) · medRxiv · doi:10.1101/2025.07.28.25332295
“Additionally, data suggest that dual-and triple agonists containing a GCGRA are superior to GLP-1RA monotherapy for weight loss [17, 22], highlighting their future potential for clinical practice.”
Gentile, M., D’Angelo, M., Varì, M. R., Bolla, A. M., Bianco, M., & Scarpioni, R. (2025) · Diabetology · doi:10.3390/diabetology6120144
“Retatrutide (LY3437943), a dual (GLP1-GIP) receptor agonist, showed substantial body weight reduction in adults with obesity [69]; a post hoc analysis of phase 2 trials suggested possible benefits for kidney function [70] and another specifically designed trial is currently ongoing (NCT05936151).”
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes
Mikhail, N. E. (2023) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2023.16.555949 · Cited by 2
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
IV CardioMIR: el Congreso de los Jóvenes Cardiólogos
Laffond, A. E., Borrego, J., Calle, D. G., & Guillén, P. L. C. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.11.001
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Bartkowiak, D., Jakubczyk, B., Lasota, A., Kopoczyński, Ł., Wiesner, M., Wodzinski, L., Boguszewski, K., Porazinski, H., Mlynarska, A., & Ratajski, O. (2026) · Cureus · doi:10.7759/cureus.116245
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
Prosecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
Dalt, L. D., Olmastroni, E., Scotti, S., D’Ardes, D., Bianconi, V., D’Onofrio, L., Gioia, L. D., Visco, V., Bencivenga, L., Salis, F., et al. (2026) · European Atherosclerosis Journal · doi:10.56095/eaj.v5i1.135
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
Manka, P. P., Kreimeyer, H., & Canbay, A. E. (2024) · Gastroenterologie up2date · doi:10.1055/a-2123-0462
Inkretin-(Co-)Agonisten: Wo geht die Reise hin?
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5066-z
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Retatrutide: prospects and potential risks in oncology and ophthalmology
Kenkishvili, A. S., Arutyunyan, M. E., & Maksimov, М. L. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2607-03
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
Dual GIP and GLP-1 agonists and changes in the lipid spectrum
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.006
Duman, T. T., Ucar, Y., Turkoglu, E. S., Tel, B. M. A., Bilgin, S., & Aktaş, G. (2026) · World Journal of Diabetes · doi:10.4239/wjd.119285 · Cited by 2
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
Galgani, J. E., Carrasco, G., Pons, G., Carrasco, F., Cortés, V., Fernández‐Verdejo, R., & Ravussin, É. (2026) · Obesity · doi:10.1002/oby.70123 · Cited by 2
Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists
Sürmeli, D., Sicinski, K. M., Dinsmore, T. C., Raman, V. S., Montanari, V., Beinborn, M., & Kumar, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00745
Real‐World Weight Loss Is Associated With a Reduction in Cancer Risk
Alkwatli, K., Xiao, H., Mariam, A., Lopetegui, N. M., Griebeler, M. L., Burguera, B. G., Pantalone, K. M., & Rotroff, D. M. (2026) · Obesity · doi:10.1002/oby.70163
Management of obesity: Going beyond eating less and moving more
Podlasek, A. (2023) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380231221001
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2610-3294
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Iannelli, A., & Carandina, S. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.01.016
AI-Based Drug Discovery of Multi-Hormone Receptor Agonists for Obesity Treatment
Rangu, J., & Ramdhave, A. S. (2025) · IEEE World AI IoT Congress (AIIoT) · doi:10.1109/aiiot65859.2025.11105373
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.